Loading...

Daniel M. Togasaki, MD, PhD

TitleAssociate Professor of Clinical Neurology
InstitutionUniversity of Southern California
DepartmentNeurology
AddressHCT 3000
Health Sciences Campus
Los Angeles CA 90089
Phone+1 323 442 5728
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Berkovich RR, Sokolov AY, Togasaki D, Yakupova AA, Cesar PH, Sahai-Srivastava S. Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study. Clin Neuropharmacol. 2018 Mar/Apr; 41(2):64-69. PMID: 29474194.
      View in: PubMed
    2. Berkovich R, Togasaki D, Cen SY, Steinman L. CD4 cell response to interval therapy with natalizumab. Ann Clin Transl Neurol. 2015 May; 2(5):570-4. PMID: 26000328; PMCID: PMC4435710.
      View in: PubMed, PubMed Central
    3. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50. PMID: 24366103; PMCID: PMC3940333.
      View in: PubMed, PubMed Central
    4. Factor SA, Wolski K, Togasaki D, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov Disord. 2013 Jun; 28(6):817-20. PMID: 23589371.
      View in: PubMed
    5. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar; 28(3):380-3. PMID: 23339054; PMCID: PMC3608707.
      View in: PubMed, PubMed Central
    6. Vuckovic MG, Wood RI, Holschneider DP, Abernathy A, Togasaki D, Smith A, Petzinger GM, Jakowec MW. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis. 2008 Nov; 32(2):319-27. PMID: 18718537; PMCID: PMC3280725.
      View in: PubMed, PubMed Central
    7. Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Vuckovic M, Fisher BE, Togasaki D, Jakowec MW. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci. 2007 May 16; 27(20):5291-300. PMID: 17507552.
      View in: PubMed
    8. Cox H, Togasaki D, Chen L, Langston JW, Di Monte DA, Quik M. The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol. 2007 May; 205(1):101-7. PMID: 17335811; PMCID: PMC2001245.
      View in: PubMed, PubMed Central
    9. Togasaki D, Hsu A, Samant M, Farzan B, DeLanney LE, Langston JW, Di Monte DA, Quik M. The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods. 2005 Jun 30; 145(1-2):159-66. PMID: 15922034.
      View in: PubMed
    10. Togasaki D, Protell P, Tan LC, Langston JW, Di Monte DA, Quik M. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology. 2005 Mar; 48(3):398-405. PMID: 15721172.
      View in: PubMed
    11. Chen L, Togasaki D, Langston JW, Di Monte DA, Quik M. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience. 2005; 132(2):409-20. PMID: 15802193.
      View in: PubMed
    12. Hsu A, Togasaki D, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther. 2004 Nov; 311(2):770-7. PMID: 15226382.
      View in: PubMed
    13. Tan LC, Protell PH, Langston JW, Togasaki D. The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord. 2002 Sep; 17(5):902-9. PMID: 12360538.
      View in: PubMed
    14. Yee RE, Huang SC, Togasaki D, Langston JW, Satyamurthy N, Barrio JR. Imaging and therapeutics: the role of neuronal transport in the regional specificity of L-DOPA accumulation in brain. Mol Imaging Biol. 2002 May; 4(3):208-18. PMID: 14537125.
      View in: PubMed
    15. Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid K, Satyamurthy N, Delanney LE, Togasaki D, Farahani KF, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord. 2001 Sep; 16(5):838-48. PMID: 11746613.
      View in: PubMed
    16. Togasaki D, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol. 2001 Aug; 50(2):254-7. PMID: 11506410.
      View in: PubMed
    17. Togasaki D, Tanner CM. Epidemiologic aspects. Adv Neurol. 2000; 82:53-9. PMID: 10624470.
      View in: PubMed
    18. Mena MA, Khan U, Togasaki D, Sulzer D, Epstein CJ, Przedborski S. Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J Neurochem. 1997 Jul; 69(1):21-33. PMID: 9202290.
      View in: PubMed
    Daniel's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (124) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (10) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑